Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from ColgatePalmolive

McDonald’s Executive Slam Elon Musk In Eye-Opening Email, Say Tweets Are ‘Perpetuating Racism’

A top executive at McDonald'sVreportedly asserted that Twitter CEO Elon Musk's "free speech" agenda at Twitter

Zenger

Elon Musk is accused by advertisers of 'perpetuating racism' on Twitter

Elon Musk's behavior as Twitter CEO and changes at the company are still off-putting to potential advertisers.

Fortune

4.9 million Fabuloso bottles are recalled over the risk of bacteria contamination

The products were sold online and at major retailers. As of the recall, no incidents or injuries had been reported.

WEKU

From analysis to the latest developments in health,
read the most diverse news in one place.

Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022

Upgrades

Benzinga

Shrinkflation bites as popular Snickers bar gets downsized

The New Daily

Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2022

Upgrades

Benzinga

Two Big Names May Become Bargain Stocks Amid Rout: Morningstar

PepsiCo particularly benefits from its nonbeverage products, including Frito-Lay and Quaker, Morningstar said.

The Street

Read news from The Economist, FT, and more,
with one subscription

Looking Into Colgate-Palmolive's Recent Short Interest

Colgate-Palmolive's (NYSE:CL) short percent of float has fallen 5.03% since its last report. The company recently reported that it has 14.22 million shares sold short, which is 1.7% of all regular shares that are available for trading.

Benzinga

Golden Cross Appears Before Colgate-Palmolive Investors

If history is any guide, there may be good fortune ahead for shares of Colgate-Palmolive (NYSE:CL). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Benzinga

Looking Into Colgate-Palmolive's Recent Short Interest

Colgate-Palmolive's (NYSE:CL) short percent of float has risen 26.96% since its last report. The company recently reported that it has 12.25 million shares sold short, which is 1.46% of all regular shares that are available for trading.

Benzinga

Colgate-Palmolive's Return On Invested Capital Insights

Pulled from Benzinga Pro data, Colgate-Palmolive (NYSE:CL) posted Q1 earnings of $603.00 million, an increase from Q4 of 220.74%. Sales dropped to $4.40 billion, a 0.09% decrease between quarters.

Benzinga

Barclays Maintains Equal-Weight Rating for Colgate-Palmolive: Here's What You Need To Know

Barclays has decided to maintain its Equal-Weight rating of Colgate-Palmolive (NYSE:CL) and lower its price target from $81.00 to $77.00. Shares of Colgate-Palmolive are trading down 0.3% over the last 24 hours, at $74.95 per share.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2022

Upgrades

Benzinga

What 7 Analyst Ratings Have To Say About Colgate-Palmolive

Colgate-Palmolive (NYSE:CL) has observed the following analyst ratings within the last quarter:

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Recap: Colgate-Palmolive Q1 Earnings

Colgate-Palmolive (NYSE:CL) reported its Q1 earnings results on Friday, April 29, 2022 at 08:30 AM. Here's what investors need to know about the announcement.

Benzinga

Colgate-Palmolive's Earnings Outlook

Colgate-Palmolive (NYSE:CL) is set to give its latest quarterly earnings report on Friday, 2022-04-29. Here's what investors need to know before the announcement. Analysts estimate that Colgate-Palmolive will report an earnings per share (EPS) of $0.75.

Benzinga

Expert Ratings For Colgate-Palmolive

Analysts have provided the following ratings for Colgate-Palmolive (NYSE:CL) within the last quarter:

Benzinga

Death Cross Looms Over Colgate-Palmolive Investors

If history is any guide, there may be trouble ahead for shares of Colgate-Palmolive (NYSE:CL). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Get all your
news in one place.

100’s of premium titles.
One news app.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.